3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Cutaneous Lymphoma: new trials by email Literature Review of Cutaneous Lymphoma trials Research Report on Cutaneous Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 43 | 2018-10-29 | 2026-06-12 |
| T-VEC in Non-melanoma Skin Cancer Talimogene Laherparepvec (T-VEC) - Non-melanoma Skin Cancer, Basal Cell Carcinoma | Phase 1 | Completed | University of Zurich | 26 | 2018-04-19 | 2022-03-18 |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Istodax, Doxil - Lymphoma, T-Cell Lymphoma | Phase 1 | Completed | Weiyun Ai | 24 | 2014-03-04 | 2020-06-09 |
| Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides Total skin electron beam therapy (TSEBT), Vorinostat - Cutaneous Lymphoma, Cutaneous T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Stanford University | 28 | 2010-12-01 | 2017-11-20 |
| ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination - Multiple Myeloma, Cutaneous Lymphoma | Phase 1 | Completed | Peter MacCallum Cancer Centre, Australia | 6 | 2005-03-01 | 2006-11-17 |
Lymphoma, T-Cell, Cutaneous (5) · Lymphoma (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma, T-Cell (1) · Lymphomatoid Papulosis (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Neoplasms (1) · Sezary Syndrome (1)
Hemic and Lymphatic Diseases (5) · Lymphoma, Non-Hodgkin (5) · Neoplasms by Histologic Type (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma, T-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Lymphoma (3) · Adenocarcinoma (1) · Blood Protein Disorders (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Cardiovascular Diseases (1)
Bendamustine Hydrochloride (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Tretinoin (1) · Vorinostat (1) · fludarabine (1) · liposomal doxorubicin (1) · romidepsin (1) · talimogene laherparepvec (1)
Peter MacCallum Cancer Centre, Australia (1) · Stanford University (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Zurich (1) · Weiyun Ai (1)
United States (3) · Australia (1) · Switzerland (1)
Ai Wei, M.D. (1) · Kirsten E Herbert, MBBS (1) · Miles Prince, MBBS (1) · Natalie Grover, MD (1) · Reinhard Dummer, Prof. Dr. (1) · Youn H Kim (1)
R01CA247497 (1)